Trial Profile

A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tirofiban (Primary) ; Tirofiban (Primary) ; Eptifibatide; Eptifibatide
Indications Myocardial infarction
Focus Adverse reactions; Therapeutic Use
Acronyms SAVI-PCI
Sponsors Medicure

04 Nov 2021 According to a Medicure media release, the key results were shared today at the Transcatheter Cardiovascular.
04 Nov 2021 Primary endpoint (The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding) has been met, according to a Medicure media release.
04 Nov 2021 Results published in the Medicure Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com